Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is Manager of Event & Health Communications, working on communications for BIO’s events and health care policy issues. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He is currently finishing up a Master’s degree in communications at Georgetown University.

Latest Posts

NPR’s Shots Blog: Vaccine Fears Fueled The Resurgence Of Preventable Diseases

outbreaksvaccineLoop

This past weekend, Michaeleen Doucleff at NPR’s Shots blog shared a fascinating but disturbing map from the Council on Foreign Relations, How Vaccine Fears Fueled The Resurgence Of Preventable Diseases. The map covers 2008-2013 and shows outbreaks of measles, mumps, rubella, polio, whooping cough, and other diseases that are preventable with vaccines. As the article notes, we’ve seen a large increase in whooping cough cases here in the US. While the 24,000 cases seen in Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Young Invincibles Still Need Flu Shot

patient

Last Friday, the CDC reported that 35 states are seeing widespread cases of influenza. Young and middle aged adults are getting hit harder than usual this season due to the prevalence of the H1N1 (swine flu) strain, according to the Pittsburgh Post-Gazette. Most years, it’s the very young and very old who are most affected. Unlike 2009, when H1N1 re-emerged after lying dormant for decades, this year’s flu shot does include protection against H1N1. However, Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

What’s Behind the Biotech IPO Boom?

BIOtech-stocks

Everyone knows that it’s been a knock-out year for the biotech sector in the public markets, which includes a large and well-performing IPO class. So far in 2013, 39 US-based companies have gone public, five European-based companies, and one Canadian company. Of these 45 IPOs, 42 companies have gone public on US stock exchanges. That’s over double the amount we saw in 2012. This year’s IPOs have also been successful at raising the amount of money Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

VIDEO: Public Policies to Promote the Innovation Economy

SBIR Reauthorization Moves Forward

What can lawmakers do to make the US more competitive globally and encourage investment in groundbreaking R&D companies? Earlier today, the Coalition of Small Business Innovators held a forum at the National Press Club to discuss proposals that would do just that. Moderated by Paul Stimers, a partner with K&L Gates, the panel included Doug Doerfler, president and CEO of MaxCyte, Ed Mathers, a partner with venture capital firm New Enterprise Associates, Katherine Hamilton, policy Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Flu Week: It’s Not Too Late to Vaccinate

Vaccination

This week is National Influenza Vaccination Week, established by the CDC to encourage people to get vaccinated as we enter the holiday season. In the past few years, estimates have shown that flu vaccination activity drops quickly after November. If you haven’t gotten your flu shot this year, it’s not too late. Flu season typically peaks in January or February, and vaccination remains beneficial as long as long as the viruses are spreading and causing Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,